Printer Friendly

IMS reports drug sales are up 5%.

LONDON -- IMS Health has estimated a 5% growth in drug sales through retail pharmacies from August of last year to August 2006. It says the top-selling drugs for that period were Lipitor, Nexium, Plavix, Seretide and Zocor.

The report covers 13 key markets.

North America posted a 6% sales expansion of $204.8 billion in the 12 months, with the key therapy growth area being cytostatics.

Overall, the largest therapeutic subcategory in dollar sales continues to be the C10 hypolipidemia class, selling at about $29.9 billion, followed by A2 antiulcerants at $22.9 billion.

Separately, IMS has announced the launch of "New Models, New Metrics," which it says provides the next generation of market measurement services to the pharmaceutical and health care industries. It encompasses several IMS initiatives that the company claims helps clients make more confident decisions as they address increasingly complex market dynamics.

"The landscape of the pharmaceutical marketplace has changed dramatically in recent years, driven by specialty products, new channels, payer pressures, emerging markets, and especially, generics growth," IMS executive vice president Gilles Pajot says. "The implications of these changes for the health care and pharmaceutical industries are profound.

For its part, he notes IMS provides information, analytics and consulting capabilities as well as global to local reach to help clients gain a deep understanding of evolving market dynamics.

The offering was developed in collaboration with IMS clients along with major pharmaceutical and generic drug industry associations and is available in the United States, Canada and South Africa as well as in 11 European Union countries.

COPYRIGHT 2006 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RX; IMS Health Inc
Publication:Chain Drug Review
Article Type:Brief article
Date:Nov 20, 2006
Previous Article:Yanai to succeed Makhov as Teva CEO in '07.
Next Article:Generics makers roll out new products.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |